Answers are grounded in this paper and cite their sources.
Controlled human infection models (CHIM) provide a crucial platform for evaluating influenza countermeasures. This dose-escalation, double-blind, randomized, placebo-controlled study aimed to establish the optimal infectious dose of a recombinant influenza A/Texas/71/2017 (H3N2) challenge strain. Healthy adults aged 18–45 received sham inoculum or 10⁴, 10⁵, or 10⁶ median tissue culture infectious dose (TCID₅₀) of challenge virus and were monitored for 7 days. The primary endpoint, attack rate (AR), required solicited symptoms combined with RT-PCR-confirmed viral shedding on ≥2 days. Mucosal and serum antibodies were measured to evaluate baseline and post-challenge immune responses. Following challenge, AR scaled with inoculum with 33.3% (10⁴ TCID₅₀; n = 4/12), 50.0% (10⁵ TCID₅₀; n = 5/10), and 77.8% (10⁶ TCID₅₀; n = 28/36) meeting the primary endpoint. Symptoms began and peaked earlier in the 10 6 group, while peak and total viral shedding were higher in, but similar between, the 10 5 and 10 6 groups. Baseline serum IgG (HA and MN) and nasal secretory IgA (HA) levels were lower in participants who developed symptomatic infection, though high inter-individual variability limited their utility as predictive correlates of susceptibility. AEs were uncommon and typically mild, and no serious adverse events occurred. Controlled human challenge with A/Texas/71/2017 (H3N2) demonstrated a maximal and efficient AR at the highest challenge dose of 10 6 TCID 50 with no apparent effect on safety. Challenge with 10 6 TCID 50 of this influenza stain offers strong potential as an efficient model for evaluating future influenza countermeasures.
No takes yet. Share an insight, caveat, or question.
McClain et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: